ChinaAnticoagulantInjection DESCRIPTION Rivaroxaban, a factor Xa inhibitor, is the active ingredient in RIVAROXABAN Tablets with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5yl}methyl)-2-thiophenecarboxamide. The molecular formula of rivaroxaban is C19H18ClN3O5S and the molecular weight is 435.89. The structural formula is: Rivaroxaban is a pure (S)-enantiomer. It is an odorless, non-hygroscopic, white to yellowish powder. Rivaroxaban is only slightly soluble in organic solvents (e.g., acetone, poly ethylene glycol 400) and is practically insoluble in water and aqueous media. Each RIVAROXABAN tablet contains 10 mg, 15 mg, or 20 mg of rivaroxaban. The inactive ingredients of RIVAROXABAN are: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Additionally, theproprietary film coating mixture used for RIVAROXABAN 10 mg tablets is Opadry鈭€ Pink and RIVAROXABAN 15 mg tablets is Opadry鈭€ Red, containing ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide, and for RIVAROXABAN 20 mg tablets is Opadry鈭€ II Dark Red, containing ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide. Mechanism of Action XARELTO is an orally bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation. Pharmacodynamics Dose-dependent inhibition of factor Xa activity was observed in humans and the Neoplastin庐 prothrombin time (PT), activated partial thromboplastin time (aPTT) and HepTest庐 are prolonged dose-dependently. Anti-factor Xa activity is also influenced by rivaroxaban. Name: Rivaroxaban Rivaroxaban is a prescription medicine used to treat the symptoms of and also to prevent Deep Vein Thrombosis (DVT) prior to hip or knee replacement surgery, prevention of Venous Thromboembolism (VTE) and restricted mobility, Nonvalvular Atrial Fibrillation and treatment of DVT and Pulmonary Embolism (PE). Rivaroxaban may be used alone or with other medications. Specification 10mg/20mg per tablet Indications Reduction Of Risk Of Stroke And Systemic Embolism In Nonvalvular Atrial Fibrillation Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Company Profile Hangzhou Jiuyuan Genetic Engineering Co., Ltd. is a national high-tech enterprise specializing in the research and development, production and sales of genetic engineering drugs, orthopedic device products and chemical drugs. The company was established in December 1993. As a member of Hangzhou East China Pharmaceutical Group Holding Co., Ltd., it is one of the earliest genetic engineering pharmaceutical companies established in Zhejiang Province and even in the whole country. Jiuyuan Gene adheres to the concept of "taking genetic engineering as the guide and contributing to human health", bravely innovating and pursuing excellence. In October 1996, the company took the lead to successfully develop and industrialize the white blood cell-boosting special drug-Jilifen (rhG-CSF), breaking the market monopoly by American and Japanese manufacturers and gaining the reputation of "China's first injection". For more than two decades, Jiuyuan Gene has successively launched Ji Lifen, Ji Pai Lin, Ji Jufen, Yi Zhe Jia, Ji Ou Ting and Bone Youdao series of products. In 2020, the company's RD center and some production lines settled in Hangzhou Pharmaceutical Town, and the level of RD and production of software and hardware has been effectively improved. With the help of academician expert workstations, post-doctoral workstations and other scientific research platforms, Jiuyuan vigorously develops the research and development of macromolecular drugs focusing on insulin and monoclonal antibodies. Based on the product positioning of both innovative drugs and generic drugs, as well as biological drugs and chemical drugs, the company focuses on the development of new drugs in the fields of tumor, blood, cardiovascular, hepatitis, and diabetes. The company has successively won many honorary titles such as National High-tech Enterprise, National Torch Program Key High-tech Enterprise, Provincial Science and Technology Progress Second Prize, Provincial Famous Trademark, and Provincial High-tech Research and Development Center. Jiuyuan Gene, with an open and enterprising spirit, gathers the resources of the Jiufang, and integrates the best of the world, in an effort to create a research and development and technological innovation as the leading, forming a biological agent as the mainstay, high-end chemical agents and innovative drugs as the supplement Product structure, and strive to cultivate an innovative pharmaceutical industrial enterprise with a more complete national market network that focuses on both the grassroots market and the central city market! Company Honor National New High-tech Enterprise Key New High-tech Enterprise of National Torch Plan National superior enterprise of intellectual property Provincial New High-tech Research Development Center FAQ Q: What's your after-sale service? A: Our quality warranty period is one year. Any quality problem will be solved to customer satisfactions. Our Services 1. Good knowledge on different market can meet special requirements. 2. Real manufacturer with our own factory located in China 3. Strong professional technical team ensure to produce the top quality products. 4. Special cost control system ensure to provide the most favorable price. 5. Rich experience on drug.ChinaAnticoagulantInjection website:http://www.jiuyuangene.net/finished-dosage-form/anticoagulant-injection/